Analysis: The Federal Reserve's new bond-buying program is essentially still QE, and stablecoins are currently the most urgent issue regarding currency quality
On December 12, former Morgan Stanley NFA trader Jeff Park posted on X, stating that the Federal Reserve's recently announced reserve management-driven purchase plan, although labeled as "reserve management," is essentially still QE, but upgraded from "quantitative easing" to "qualitative easing." Under an ample reserves system, reserves have perfect balance sheet flexibility due to a 0% risk weight under LCR, far superior to short-term Treasury bonds. This also explains why the SLR rules were suddenly relaxed before Thanksgiving and why a $40 billion monthly purchase plan was quickly announced within two weeks before the end of QT. In short, short-term Treasury bonds are "near money," but reserves are "perfect money." In addition, Jeff Park added that stablecoins are currently the most urgent "money quality" issue, which is also why cryptocurrencies can never truly disappear.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Supply disruptions ease, oil market bears “swiftly gather”: Brent put option bets surge to unprecedented levels
Oil traders are flocking to buy options, betting on a decline in Brent crude. As investors reposition after a sharp rise in oil prices over the past few trading sessions, bearish bets have surged to unprecedented levels.

Bridgford Foods VP Richard Eugene Bridgford acquires USD 2,054.5 in common shares
New York Federal Reserve official: U.S. Treasury purchases have no preset path, will closely monitor financing market pressures in October
Lorie K. Logan, head of the New York Fed's Markets Group, stated that the Federal Reserve will continue to assess the reserve levels within the banking system. The purchase of U.S. Treasuries for reserve management does not follow a predetermined path and may be adjusted in the future based on market conditions.
Structure Therapeutics CMO Blas Coll Crespo disposes of USD 124,008 common shares
